EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Vitamin D did not reduce multiple sclerosis disease activity after a clinically isolated syndrome

Helmut Butzkueven, Anne-Louise Ponsonby iD, Mark S Stein, Robyn M Lucas iD, Deborah Mason, Simon Broadley iD, Trevor Kilpatrick, Jeannette Lechner-Scott, Michael Barnett iD, William Carroll iD, Peter Mitchell, Todd A Hardy und 17 weitere

Brain · 2024

DOI: 10.1093/brain/awad409 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Brain, 2024. Verfasst von Helmut Butzkueven und 28 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neuroscience, Central Clinical School, Monash University, Melbourne, VIC 3004, Australia. Hauptthemen laut MEDLINE: Demyelinating Diseases, Multiple Sclerosis, Vitamin D. Die Arbeit wurde bisher 36-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: PREVANZ.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Low serum levels of 25-hydroxyvitamin D [25(OH)D] and low sunlight exposure are known risk factors for the development of multiple sclerosis. Add-on vitamin D supplementation trials in established multiple sclerosis have been inconclusive. The effects of vitamin D supplementation to prevent multiple sclerosis is unknown. We aimed to test the hypothesis that oral vitamin D3 supplementation in high-risk clinically isolated syndrome (abnormal MRI, at least three T2 brain and/or spinal cord lesions), delays time to conversion to definite multiple sclerosis, that the therapeutic effect is dose-dependent, and that all doses are safe and well tolerated. We conducted a double-blind trial in Australia and New Zealand. Eligible participants were randomized 1:1:1:1 to placebo, 1000, 5000 or 10 000 international units (IU) of oral vitamin D3 daily within each study centre (n = 23) and followed for up to 48 weeks. Between 2013 and 2021, we enrolled 204 participants. Brain MRI scans were performed at baseline, 24 and 48 weeks. The main study outcome was conversion to clinically definite multiple sclerosis based on the 2010 McDonald criteria defined as either a clinical relapse or new brain MRI T2 lesion development. We included 199 cases in the intention-to-treat analysis based on assigned dose. Of these, 116 converted to multiple sclerosis by 48 weeks (58%). Compared to placebo, the hazard ratios (95% confidence interval) for conversion were 1000 IU 0.87 (0.50, 1.50); 5000 IU 1.37 (0.82, 2.29); and 10 000 IU 1.28 (0.76, 2.14). In an adjusted model including age, sex, latitude, study centre and baseline symptom number, clinically isolated syndrome onset site, presence of infratentorial lesions and use of steroids, the hazard ratios (versus placebo) were 1000 IU 0.80 (0.45, 1.44); 5000 IU 1.36 (0.78, 2.38); and 10 000 IU 1.07 (0.62, 1.85). Vitamin D3 supplementation was safe and well tolerated. We did not demonstrate reduction in multiple sclerosis disease activity by vitamin D3 supplementation after a high-risk clinically isolated syndrome.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Demyelinating DiseasesMultiple SclerosisVitamin DHumansCalcifediolCholecalciferolDouble-Blind MethodVitaminsMaleFemale

Stichwörter der Autor:innen

clinical trialmultiple sclerosisvitamin D

Substanzen

CalcifediolCholecalciferolVitamin DVitamins

Autor:innen und Institutionen

  • Department of Neuroscience, Central Clinical School, Monash University, Melbourne, VIC 3004, Australia.
  • Florey Institute of Neuroscience and Mental Health, University of Melbourne, Melbourne, VIC 3010, Australia.
  • Department of Diabetes and Endocrinology, The Royal Melbourne Hospital, Parkville, VIC 3010, Australia.
  • National Centre for Epidemiology and Public Health, Australian National University, Canberra, ACT 0200, Australia.
  • Department of Neurology, Christchurch Hospital, Christchurch 8011, New Zealand.
  • Department of Neurology, School of Medicine and Dentistry, Griffith University, Southport, QLD 4222, Australia.

ORCID-Profile: Anne-Louise Ponsonby, Robyn M Lucas, Simon Broadley, Michael Barnett, William Carroll, Tomas Kalincik, Bruce V Taylor

Förderung

  • PREVANZ

Zitieren

APA

Butzkueven, H., Ponsonby, A. L., Stein, M. S., Lucas, R. M., Mason, D., Broadley, S., Kilpatrick, T., Lechner-Scott, J., Barnett, M., Carroll, W., Mitchell, P., Hardy, T. A., Macdonell, R., McCombe, P., Lee, A., Kalincik, T., van der Walt, A., Lynch, C., Abernethy, D., …, & PREVANZ Investigators (2024). Vitamin D did not reduce multiple sclerosis disease activity after a clinically isolated syndrome. Brain. https://doi.org/10.1093/brain/awad409

Vancouver

Butzkueven H, Ponsonby AL, Stein MS, Lucas RM, Mason D, Broadley S, et al. Vitamin D did not reduce multiple sclerosis disease activity after a clinically isolated syndrome. Brain. 2024. doi:10.1093/brain/awad409

BibTeX
@article{Butzkueven2024,
  author = {Butzkueven, Helmut and Ponsonby, Anne-Louise and Stein, Mark S and Lucas, Robyn M and Mason, Deborah and Broadley, Simon and Kilpatrick, Trevor and Lechner-Scott, Jeannette and Barnett, Michael and Carroll, William and Mitchell, Peter and Hardy, Todd A and Macdonell, Richard and McCombe, Pamela and Lee, Andrew and Kalincik, Tomas and van der Walt, Anneke and Lynch, Chris and Abernethy, David and Willoughby, Ernest and Barkhof, Frederik and MacManus, David and Clarke, Michael and Andrew, Julie and Morahan, Julia and Zhu, Chao and Dear, Keith and Taylor, Bruce V and PREVANZ Investigators, PREVANZ Investigators},
  title = {Vitamin D did not reduce multiple sclerosis disease activity after a clinically isolated syndrome},
  journal = {Brain},
  year = {2024},
  doi = {10.1093/brain/awad409}
}
Kostenlos starten →